Live Now Button (3)

Unlocking Future Insights in Biologics Research & Development

18 - 19 March 2027
InterContinental London, London, UK

Now: Afternoon Sessions

Follow along live as industry leaders unveil the latest advancements in biomedicine. 

15:05

Panel Discussion: NextGen Vaccine Strategies To Advance Cancer Treatment
Moderator: ANTONIO POSTIGO, Chief Scientific Officer, Stratosvir Ltd

Panel Discussion: The Next Chapter Of Oligonucleotide Delivery
Moderator: STEVE HOOD, Senior Director, Oligonucleotide ADME Strategy, DMPK, GSK

Empowering Antibody Engineering – Highlights From Early Beginnings Of Using AI-Based Tools For Optimization & Functional Engineering Of Antibody Candidates
BERIT OLSEN KROGH, Senior Research Fellow, Lundbeck

Panel Discussion: Mixed Modalities: Addressing The Challenges & Opportunities To Drug The Undruggable

Multivalent Ligand Design To Selectively Bind Proteins
NATHAN ALVES, Research Director, Indiana University School Of Medicine

15:30

Cyclotides As Ultra-Stable Combinatorial Display Platforms For Peptide-Based Drug Discovery
DAVID CRAIK, Professor, University Of Queensland

Enhancing Biologics Lead Optimisation By Combining Affinity Prediction Methods & Active Learning
OWEN VICKERY, Associate Principal Scientist, AstraZeneca

InSiDe Out: In Silico Developability Screening At AstraZeneca, Impact To Date & Future Direction
ISABELLE SERMADIRAS, Associate Principal Scientist, AstraZeneca

15:55

Unveiling Hidden Targets: AI-Driven Discovery Of Therapeutic Cancer Antigens From The Dark Genome
CHRISTIAN GARDE, Director, Evaxion

The Identification Of Cyclic Peptide Metabolic Soft Spots By Isotope-Labelled Reductive Dimethylation & Leveraging High-Resolution Ion Mobility-Mass Spectrometry
MARIA FAWAZ, Associate Principal Scientist, MS

Using The Very Small To Tackle The Very Large – Our Journey From Concept To Clinic
IJEOMA UCHEGBU, Professor Of Pharmaceutical Nanoscience, University College London

First-In-Class Site-Directed Targeted soloMER Drug Conjugate For Autoimmune Inflammation
OBINNA UBAH, Principal Scientist, Elasmogen

Rationalising MABs Developability Testing
DAVID BROCKWELL, Professor, University Of Leeds

16:20

Development & Qualification Of A Cell-Based Potency Assay For Two Novel DNA Cancer Vaccine
ELISA MARELLI, Research Scientist, Scancell

Short Novel Peptides As Chelating Agents For Metal-Related Diseases
MICHAL SHOSHAN, Founder & Chief Executive Officer, metaLead Therapeutic

Purification Of Oligonucleotides & Their Conjugates For Progressing Early Drug Discovery Projects & The Chromatographic Challenges With Oligonucleotide G-rich Sequences
YIPING WU, Senior Scientist, AstraZeneca

Removing Biological Roadblocks To Better Treatments: The Power Of Nanofitin-Enhanced Biologics
MATHIEU CINIER, Scientific Director, Affilogi

Share Your NextGen Biomed Moments

We'd love to see your favourite moments and photos on social media! Use the hashtags #NextGenBiomed2025 and #NGB2025, and tag our official accounts below.

The Antibody Society (padding)

NextGen Biomed 2026 is proudly
partnered
with The Antibody Society

NextGen Biomed Square

About

Discover more about our ecosystem of channels for the biologics R&D community

Attend Image

Attend

Be part of the new wave of Biomed R&D innovation

Partner Image

Partner

Showcase your offering to leading pharma and biotech decision makers

Whats On Image

What's On

Explore dynamic panels, engaging roundtables, and hands-on workshops

NextGen Biomed 2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration, including:

Proteins, Antibodies & ADCs
Panel Discussion: What Is The Next Game Changer In Antibody Engineering?

Moderator: Karen Silence, Head Preclinical Product Development, ArgenX
Panellists include Berit Olsen Krogh, Senior Research Fellow, Lundbeck; Andrew Buchanan, Principal Scientist, AstraZeneca

Peptides
Presentation: What Does The Future Hold For Orally Available Peptides?

Presented by: Immanuel Lerner, Chief Executive Officer, 
Pepticom

Oligonucleotides
Panel Discussion: The Next Chapter Of Oligonucleotide Delivery

Moderator: Steve Hood, Senior Director, Oligonucleotide ADME Strategy, GSK
Panellists include 

Saul Martinez Montero, Senior Director, RNA Therapeutics, Dyne Therapeutics
Morten Lindow, RNAHub Founder & Mission Lead, Roche
Sritama Bose, Head Of Chemistry Research & Innovation, NATA
Fazel Shabanpoor, Co-Founder & Chief Scientific Officer & Associate Professor & Head Of Pep & Oligo Therapeutics Lab, Centron Bio & The Florey Institute

 

Sustainability in Tides & Biologics
Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches

Moderator: Walter Cabri, Full Professor of Organic Chemistry, University of Bologna
Panellists include Daniel Sejer Pedersen, Chemical Development Specialist CMC API Development, Novo Nordisk;
Anna Maria Papini, Full Professor & Group Leader, University of Florence;
Louis Diorazio, Senior Principal Scientist, New Modalities, AstraZeneca;
Alessandra Tolomelli, Associate Professor, University of Bologna

Immunotherapy & Immuno-oncology
Presentation: How Vaccines & Immunotherapy Strategies: Converging Pathways For Preventing Or Treating Chronic Diseases

Presented by: Daniel Larocque, Innovation Lead, Innovation & Emerging Science, Sanofi

NextGen Biomed 2026 Speakers:

Alexander Eggermont
Professor Immunotherapy of Cancer,
University Medical Center Utrecht
Anders Gabrielsen
Vice President & Head of Global Clinical Development,
Ribocure
Andrew Feilden
Senior Director Analytical Science,
Bicycle Therapeutics
Anna Perdrix
co-CEO,
Sixfold Bioscience
Brian Schanen
Head of Biomarker Research for the mRNA Center of Excellence,
Sanofi
Chris Herring
Vice President of Biology & Safety,
T-Therapeutics
Daniel Fleischanderl
Director Upstream Development,
Boehringer Ingelheim
Daniel Larocque
Innovation Leader,
Sanofi
Fernando Albericio
Research Professor,
University of KwaZulu-Natal
Hannah Bolt
Head of Peptide Discovery, Director,
AstraZeneca
Joanna Calvert
Senior Programme Manager - UK Vaccine Innovation Pathway,
NIHR
Karen Silence
Vice President, Head of Preclinical Product Development ,
Argenx
Lilly Wollman
Co-Founder & Chief Executive Officer,
Synteny
Livija Deban
Chief Scientific Officer,
Prokarium
Marion Fresch
Senior Scientist QC,
Bachem
May Sabry
Senior Director, Precision Medicine,
AstraZeneca
Morten Meldal
Professor, Department of Chemistry,
Københavns Universitet
Paul Kellam
Chief Scientific Officer,
RQ Biotechnology
Prasun Chakraborty
CEO and Founder,
Genevation LTD
Simon Plyte
CSO,
Biomunex Pharmaceuticals
Agnieszka Lewandowska
Associate Director Analytical Development,
Immunocore
Aidan Riley
Associate Director,
AstraZeneca
Alessandra Tolomelli
Professor,
University of Bologna
Alexander Davydov
Community Contribution Lead,
OHDSI
Alexandra Sevko
Vice President, Translational Science,
Amphista
Ali Roghanian
Associate Professor in Cancer Immunotherapy,
University of Southampton
Allan Bradley
CSO,
T-Therapeutics
Alsya Affandi
Lead Scientist,
Amsterdam UMC, Immunara Tx
Amberley Stephens
Associate Principal Scientist,
AstraZeneca
Amjad Khan
Former Global Digital Client Partner for Vaccines,Hospital and Medical Affairs,
Pfizer Ltd
Anders Dahlén
Senior Director,
AstraZeneca
Andreas Hollenstein
Senior Principal Scientist,
Roche
Andreas Plueckthun
Professor Of Biochemistry, Director, Department Of Biochemistry,
University of Zurich
Andrew Henry
Principal Scientist,
Chemical Computing Group
Angus Sinclair
Chief Scientific Officer,
LabGenius Therapeutics
Anis Gammage
Principal (Head of Scoping),
Deep Science Ventures
Annabelle Herrington-Symes, PhD
Biologics Discovery & Development Senior Scientist,
LifeArc
Antima Gupta
Senior Application Scientist,
Collaborative Drug Discovery
Apolline Lefevre
Clinical Pharmacology Sciences & Analytics,
Roche
Barbara Ciani
Senior Lecturer,
University of Sheffield
Beth Wensley
Principal Scientist - Protein and Analytical Sciences,
LifeArc
Birgit Piater
Associate Scientific Director, ADC Biology,
Merck KGaA
Blake Mazzitelli
Senior Scientist II,
Maxion Therapeutics
Brenda Iglesias
Associate Director, Strategic Partnerships,
GSK
Brian Weinert
Principal Scientist & Discovery Project Lead,
Nykode Therapeutics
Callum Scott
Head of Development,
Scancell Ltd
Campbell Stewart
Principal,
Novo Holdings
Catherine Stace
Executive Vice President,
Kuano
Cécile Brocard
Head of Downstream Development,
Boehringer Ingelheim
Cerlin Roberts
Founder & Chief Executive Officer,
Oxford Global
Charles Johannes
Co-Founder & President,
FogPharma
Charlotte Deane
Professor,
Centre for Medicines Discovery
Christian Garde
Director, Bioinformatics,
Evaxion AI
Christian Hunzinger
Senior Director CMC Development Proteins, ADCs. & Clinical Entities,
BioNTech
Christopher Lloyd
Director,
AstraZeneca
Christopher Ullman
Chief Executive Officer,
Stratosvir Ltd
Colby Souders
CSO,
Twist Bioscience
Colette Johnston
VP - Head of Product Platform Research,
Enara Bio
Dan Kristensen
Scientific Director,
Symphogen A/S
Darryl Hayward
Antibody Discovery Scientist,
GSK
David Rodríguez
Associate Director,
Novo Nordisk
Denise Steckel
Head of Clinical Collaborations Development,
Genentech
Dennis Ungan
Principal Scientist,
Novartis
Dimitri Sideris
Senior Scientist,
AstraZeneca
Dorothy Bray
Director,
Celtic Biotech
Ebru Dogruol
Vice President Commercial,
Pfizer
Elaine Dymond
Managing Director,
Dymond Pharma Consultancy Limited
Elisabetta Bianchi
Director of Discovery Chemistry,
Curium Biopharma
Erik Briers
Board Member,
WeCan Foundation & Europa Uomo
Esam Abualrous
Principal Scientist I, Applications Science,
Schrödinger
Fabien Rousset
Director Global Innovation,
PolyPeptide Group
Fabio Centola
CQA Manager,
Merck & Cie KmG
Federico Riccardi Sirtori
Director, Head of NBE-DMPK Innovative Bioanalytics,
Merck & Cie KmG
Felix Wojcik
Principal Scientist,
Novo Nordisk
Florian Bossard
Scientific Sales Manager,
Vixen Bio
Freddie Martin
Senior Scientist I, Applications Science,
Schrödinger
Gokhan Yahioglu
Co-Founder & Director of Chemistry,
Antikor Biopharma
Gry Persson
Senior Project Manger, Infectious Diseases,
evaxion.ai
Gurdaman Singh
Scientific Investigator,
GSK
Hans Melo
Chief Executive Officer,
Menten AI
Hans van der Vliet
Professor, Medical Oncologist,
Amsterdam UMC
Harry Taylor
Senior Project Manager,
Photene
Heinrich Haas
Chief Technology Officer,
Neovacs
Henrik Ihre
Distinguished Fellow, R&D,
Cytiva
Hussein Al-Mossawi
Fellow and Lecturer in Pathology & Immunology,
University of Oxford
Ivan Gladwyn-Ng
Business Development Senior Scientist,
Cyagen
James Legg
Chief Scientific Officer,
Cytospire Therapeutics
Jennifer Mataraza
Executive Director and Head, Translational Immuno-Oncology,
Novartis Institutes For Biomedical Research
Jerome Mastio
In Vivo Associate Principal Scientist,
AstraZeneca
Joel Benjamin Heim
Senior Project Manager,
Nykode Therapeutics
John Bridgeman
Cso,
Immunokey
Joost Uitdehaag
Head of Biology,
Crossfire Oncology B.V.
Justyna Mysliwy
Executive Director of Research,
Iksuda Therapeutics
Kai Hilpert
Professor,
City St George's, University of London
Kamaraj Karunanithi
Director of Research and Innovation,
University Hospitals of North Midlands NHS Trust
Karin Hrovatin
Bioinformatic Scientist,
Merck KGaA
Kate Smith
UK Head Protein And Cell Sciences,
GlaxoSmithKline
Katy Lloyd
Associate Director,
Genmab
Ken Chow
Health Tech Counsel,
Flanders Investment & Trade, Belgium Embassy (London)
Larisa Soldatova
Professor & Reader in Data Science,
University of London
Laura Acqualagna
Director of AI/ML Engineering,
GSK
Lei Shi
Senior Vice President,
Biointron
Louise Brackenbury
Science Director,
Charles River Laboratories
Lukas Leder
Senior Principal Scientist,
Novartis
Mali Eskandarpour
Senior Research Fellow,
University College London
Manuel Vega
Chief Executive Officer,
AGS Therapeutics
Marc Siggel
Senior Scientist,
Merck KGaA
Marc Vendrell
Professor of Translational Chemistry,
University of Edinburgh
Maria Ascierto
Professor Translational Cancer Immunology; Head Scotland CRUK Clinical Biomarkers Hub,
University of Glasgow
Mariolina Salio
Director Experimental Immunology,
Immunocore
Marjolein Van Egmond
Professor in Oncology and Inflammation,
Amsterdam UMC Genome Diagnostics
Mark Austin
Associate Director In vitro Display,
AstraZeneca
Mark Eccleston
CEO,
Valirx
Matthew Burke
Senior Scientist,
UCB
Mattia Cocco
Associate Director,
AstraZeneca
Michael Anyadiegwu
CMC Technology Lead,
CEPI
Michael Delaney
Senior Principal Scientist,
Novo Nordisk
Michelle Barnard
Director of Research,
ValiRx
Miguel Gaspar
Senior Director, Oncology R&D,
Astrazeneca
Mihaela Bozic
Scientist,
T-Therapeutics Ltd
Mikhail Kuravskiy
Principal Scientist,
UCB
Mohammad Arastoo
Research Fellow,
University of Aberdeen
Nathan Alves
Research Director,
Indiana University School of Medicine
Nathaniel Goldberg
R&D Scientist II,
Aralez Bio
Nazim Uddin
Senior Development Scientist,
Scancell
Nehil Chaturvedi
Senior Technical Project Lead,
Leukocare AG
Ni Huang
Associate Director,
T-Therapeutics Ltd
Nicola Bonzanni
Founder and CEO,
ENPICOM
Nicola Burgess-Brown
Professor,
UCL
Obinna Ubah
Principal Scientist & Programme Lead,
Elasmogen
Omar Aziz
Scientific Business Director,
Charles River Laboratories
Paolo Marcatili
Head of Antibody Design,
Novo Nordisk
Peter Molloy
Senior Fellow, Protein Engineering,
Immunocore
Philip Gaskin PhD
Director of Business Development,
The Jackson Laboratory
Poorvaja Ganesan
Scientist III Upstream Process Development,
Alexion Pharmaceuticals, Inc.
Rémi Palmantier
CEO,
ImmThera Consuting SAS
Rhiannon Jenkinson
Chief Scientific Officer,
Nexus Bioquest
Ricardo Carreira
Associate Director,
Immunocore
Rikhav Gala
Group Leader - Senior Principal Scientist,
Pfizer Ltd
Russell LaMontagne
Chief Executive Officer,
BITT
Saif Shubber
Associate Director,
Bicycle Therapeutics
Sara Trabulo
CMC & Analytical Development,
AstraZeneca
Sarah Harris
Professor of Biological and Materials Physics,
University of Sheffield
Sebastian Birkedal
Senior Scientist Downstream Process Development,
Byondis
Sebastian Wolfgang Draxler
Principal Scientist Analytics,
Bayer
Sepideh Afshar
Senior Director,
Genentech
Sergio Martinez Cuesta
Principal Data Scientist,
AstraZeneca
Shashi Jatiani
Director,
SeromYx Systems Inc
Silvia Crescioli
Antibody Therapeutics Pipeline Expert,
Independent Consultant
Simon Brunner
Principal,
Flagship Pioneering
SM Chen
researcher,
Asymchem
Sofie Voet
Principal Scientist,
argenx
Sonia Macia
Chief Medical Officer,
OneChain Therapeutics
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Sridhar Neelamraju
Associate Principal Informatician,
AstraZeneca
Sritama Bose
Associate Director of Chemistry,
Orfonyx Bio
Steffen Goletz
Professor, Department of Biotechnology and Biomedicine,
Danish Technical University
Stephanie Linker
Senior Computational Biochemist,
Merck & Cie KmG
Stephen Lock
Senior market development manager,
SCIEX
Steve Hood
Senior Director,
GSK
Steven Rust
Head of Protein Biotherapeutics,
Biotech in Stealth
Sudhir Agrawal
President & Founder & Affiliate Professor,
Arnay Sciences
Sue Charlton
Head of Clinical Evaluation,
UK Health Security Agency
Supriyadi Hafiz
Senior Scientist,
Merck
Takashi Ebihara
COO,
GeneFrontier Corporation
Thomas Kofoed
Chief Executive Officer,
Alphalyse
Tiffany Rau
Professor,
University of College Cork & Owner, Bio Pharma Technical Consulting
Tobias Von Der Haar
Professor,
University of Kent & Jantomarna Therapeutics Ltd
Tom Bosschaerts
Chief Operations Officer,
ImmuneWatch
Vaios Karanikas
Biomarker Portfolio Leader,
Roche
Vicky Brentville
Principle Scientist,
Scancell
Victor Goldmacher
Chief Scientific Officer,
Immuvia Therapeutics
Vivek Verma
Lecturer,
Imperial College London
Walter Cabri
Professor,
University of Bologna
Wenhui Song
Professor,
University College London
Xi Zhao
Head, Oncology Bioinformatics, Research & Development,
AbbVie
Xinxin Gao
Senior Principal Scientist,
Genentech
Yashas Kannan
Vice President Drug Discovery,
PentaBind
Yi-Ru Yu
Lead Scientist,
Pilatus Biosciences SA
Yongqun He
Professor,
University of Michigan
GenScript

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

 

Advanced Therapies Specialist Team Leader,
Genscript

Biosystems Acro

Biologics 2024 has been one of the best events I have attended so far in my career.

 

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Bioassay

 

Impressed by the effort to bring people together.

 

Business Development Director,

Bioassay

IpA

 

Nice set-up, with good support for exhibitors

 

Director of Client Relations,

ImmunoPrecise

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

2025 Sponsors Include

Register Now

Be part of the new wave of Biomed R&D innovation,